How can the CREDENCE data be applied to people with Type 2 Diabetes Mellitus (T2DM)
Follow this link for Prescribing Information and Adverse Events Reporting - https://www.invokana.co.uk/assets/documents/invokana-prescribing-information.pdf
This promotional symposium has been organised and funded by Napp Pharmaceuticals Limited and is intended for Healthcare Professionals.
This promotional symposium will focus on the CREDENCE trial and what this means for the treatment of T2DM in clinical practice. We will explore the recent license extension to Invokana® and how this could change your management of individuals with Diabetic Kidney Disease (DKD) in T2DM.
Learning objectives:
· Review the holistic picture of clinical management of type 2 diabetes: beyond glucose control
· Understand the importance of testing to identify diabetic kidney disease
· Summarise the findings of the CREDENCE trial
· Translate the CREDENCE trial into a real-world perspective
· Discuss practical applications of the above evidence
UK-INV-2000076
November 2020